Amy Marren

1.2k total citations · 1 hit paper
26 papers, 919 citations indexed

About

Amy Marren is a scholar working on Genetics, Epidemiology and Immunology. According to data from OpenAlex, Amy Marren has authored 26 papers receiving a total of 919 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Genetics, 17 papers in Epidemiology and 7 papers in Immunology. Recurrent topics in Amy Marren's work include Inflammatory Bowel Disease (21 papers), Microscopic Colitis (16 papers) and Pregnancy and Medication Impact (5 papers). Amy Marren is often cited by papers focused on Inflammatory Bowel Disease (21 papers), Microscopic Colitis (16 papers) and Pregnancy and Medication Impact (5 papers). Amy Marren collaborates with scholars based in United States, Canada and United Kingdom. Amy Marren's co-authors include Séverine Vermeire, Sadiq Lula, Ann Gils, Paul J. Healey, Julián Panés, William J. Sandborn, Gary Chan, Bruce E. Sands, Chinyu Su and Jean‐Frédéric Colombel and has published in prestigious journals such as SHILAP Revista de lepidopterología, Gastroenterology and Gut.

In The Last Decade

Amy Marren

26 papers receiving 902 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials

2017 296 citations Julián Panés, William J. Sandborn et al. Gut profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Amy Marren United States	10	589	331	328	209	192	26	919
Mark R. Fleisher United States	10	674 1.1×	429 1.3×	520 1.6×	220 1.1×	105 0.5×	17	1.2k
Judith Collins United States	9	1.3k 2.2×	357 1.1×	1.0k 3.1×	354 1.7×	116 0.6×	18	1.7k
Joyce Ford United States	10	317 0.5×	356 1.1×	203 0.6×	83 0.4×	123 0.6×	15	699
Hanzhe Zheng United States	6	717 1.2×	214 0.6×	572 1.7×	187 0.9×	149 0.8×	13	895
Jeroen M. Jansen Netherlands	19	1.2k 2.1×	442 1.3×	944 2.9×	362 1.7×	156 0.8×	48	1.5k
Yulia Ron Israel	14	793 1.3×	411 1.2×	600 1.8×	273 1.3×	115 0.6×	47	1.1k
G. D’Haens Netherlands	12	985 1.7×	211 0.6×	851 2.6×	380 1.8×	73 0.4×	37	1.2k
Philip V. Hassard United States	7	481 0.8×	83 0.3×	270 0.8×	134 0.6×	409 2.1×	13	911
B Huang Canada	9	893 1.5×	199 0.6×	770 2.3×	269 1.3×	81 0.4×	32	1.0k
Paul Pollack United States	10	1.4k 2.3×	490 1.5×	1.1k 3.3×	440 2.1×	102 0.5×	29	1.7k

Countries citing papers authored by Amy Marren

Since Specialization

Citations

This map shows the geographic impact of Amy Marren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy Marren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy Marren more than expected).

Fields of papers citing papers by Amy Marren

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy Marren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy Marren. The network helps show where Amy Marren may publish in the future.

Co-authorship network of co-authors of Amy Marren

This figure shows the co-authorship network connecting the top 25 collaborators of Amy Marren. A scholar is included among the top collaborators of Amy Marren based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy Marren. Amy Marren is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Panaccione, Remo, John D. Isaacs, Lea Ann Chen, et al.. (2020). Correction to: Characterization of Creatine Kinase Levels in Tofacitinib‑Treated Patients with Ulcerative Colitis: Results from Clinical Trials. Digestive Diseases and Sciences. 66(9). 3214–3215. 1 indexed citations

Panaccione, Remo, John D. Isaacs, Lea Ann Chen, et al.. (2020). Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials. Digestive Diseases and Sciences. 66(8). 2732–2743. 11 indexed citations

Boeri, Marco, et al.. (2019). Patient and physician preferences for ulcerative colitis treatments in the United States. SHILAP Revista de lepidopterología. 2 indexed citations

Sands, Bruce E., Alessandro Armuzzi, John K. Marshall, et al.. (2019). Efficacy and safety of tofacitinib dose de‐escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open. Alimentary Pharmacology & Therapeutics. 51(2). 271–280. 65 indexed citations

Boeri, Marco, Amy Marren, Marco DiBonaventura, et al.. (2019). <p>Patient and physician preferences for ulcerative colitis treatments in the United States</p>. Clinical and Experimental Gastroenterology. Volume 12. 263–278. 39 indexed citations

Hanauer, Stephen B., David T. Rubin, Paolo Gionchetti, et al.. (2019). 836 Tofacitinib Efficacy in Patients With Moderate to Severe Ulcerative Colitis: Subgroup Analyses of OCTAVE Induction 1 & 2 and OCTAVE Sustain by 5-Aminosalicylates Use. The American Journal of Gastroenterology. 114(1). S483–S484. 2 indexed citations

Vermeire, Séverine, et al.. (2018). Immunogenicity of biologics in inflammatory bowel disease. Therapeutic Advances in Gastroenterology. 11. 1756283X17750355–1756283X17750355. 174 indexed citations

Panés, Julián, William J. Sandborn, Stefan Schreiber, et al.. (2017). Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials. Gut. 66(6). 1049–1059. 296 indexed citations breakdown →

Pasquale, Margaret K., Chinyu Su, Amy Marren, et al.. (2017). Ulcerative Colitis Treatment Patterns and Cost of Care. Value in Health. 20(6). 752–761. 31 indexed citations

10.

Mahadevan, Uma, Daniel C. Baumgart, Marla C. Dubinsky, et al.. (2017). Pregnancy Outcomes in the Tofacitinib Ulcerative Colitis OCTAVE Studies. The American Journal of Gastroenterology. 112. S410–S411. 3 indexed citations

11.

Pasquale, Margaret K., et al.. (2016). ULCERATIVE COLITIS TREATMENT PATTERNS AND COST OF CARE. Value in Health. 19(3). A314–A314. 1 indexed citations

12.

Marren, Amy. (2016). Tofacitinib is not a biologic. Annals of Gastroenterology. 30(1). 134–134. 6 indexed citations

13.

Clowse, Megan E. B., Steven R. Feldman, John D. Isaacs, et al.. (2016). Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis. Drug Safety. 39(8). 755–762. 115 indexed citations

14.

Lula, Sadiq, et al.. (2016). Systematic Literature Review on the Immunogenicity of Biologics in Inflammatory Bowel Disease. The American Journal of Gastroenterology. 111. S410–S410. 1 indexed citations

15.

Panés, Julián, William J. Sandborn, Stefan Schreiber, et al.. (2016). 855 Efficacy and Safety of Tofacitinib for Oral Induction Therapy in Patients With Moderate to Severe Crohn's Disease: Results of a Phase 2B Randomized Placebo-Controlled Trial. Gastroenterology. 150(4). S182–S183. 10 indexed citations

16.

Rubin, David T., et al.. (2016). Communication Between Physicians and Patients with Ulcerative Colitis: Insights from Studies of Patient-Doctor Visits. The American Journal of Gastroenterology. 111. S280–S281. 1 indexed citations

17.

D’Haens, Geert, Remo Panaccione, Peter Higgins, et al.. (2016). 856 Efficacy and Safety of Oral Tofacitinib for Maintenance Therapy in Patients With Moderate to Severe Crohn's Disease: Results of a Phase 2B Randomized Placebo-Controlled Trial. Gastroenterology. 150(4). S183–S183. 7 indexed citations

18.

Panés, Julián, Chinyu Su, Amy Marren, et al.. (2016). Tu2003 Improvement in Patient-Reported Outcomes in Two Phase 3 Induction Studies of Tofacitinib in Patients With Moderately to Severely Active Ulcerative Colitis. Gastroenterology. 150(4). S1003–S1003. 1 indexed citations

19.

Sands, Bruce E., Geert D’Haens, William J. Sandborn, et al.. (2016). Tofacitinib Has Induction Efficacy in Moderately to Severely Active Ulcerative Colitis, Regardless of Prior TNF Inhibitor Therapy. The American Journal of Gastroenterology. 111. S261–S261. 4 indexed citations

20.

Marren, Amy, et al.. (2015). THU0173 Pregnancy Outcomes in the Tofacitinib RA Safety Database Through April 2014. Annals of the Rheumatic Diseases. 74. 256–257. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact